https://ebdgroup.knect365.com/biotech...
Gene therapies are currently one of the hottest therapeutic properties. Speaking on the sidelines of Biotech Showcase 2019, Julien Pham, President and COO of Genprex, describes to Mike Ward how the company is using a technology platform which wraps the TUSC2 gene in a cholesterol nanoparticle to create Oncoprex which, in combination with erlotinib, is in Phase II testing against NSCLC. Genprex also plans to start a Phase I trial of Oncoprex plus immunotherapies in the near future.